Showing results (1841-1850 of 1,955) with videos related to

Sort By:
Pageof 196
Scientific Reports|October 25, 2016
Use of next generation sequence to investigate potential novel macrolide resistance mechanisms in a population of Moraxella catarrhalis isolatesYa-Li Liu, Dong-Fang Li, He-Ping Xu, et al.
Cell Host & Microbe|June 2, 2022
Gut bacterial isoamylamine promotes age-related cognitive dysfunction by promoting microglial cell deathYun Teng, Jingyao Mu, Fangyi Xu, et al.
Optics Letters|July 16, 2020
Low-loss fs-laser-written surface waveguide lasers at >2  µm in monoclinic Tm<sup>3+</sup>:MgWO<sub>4</sub>Esrom Kifle, Pavel Loiko, Javier Rodríguez Vázquez de Aldana, et al.
International Journal of Biological Sciences|August 19, 2022
MiR-138-5p Targets MACF1 to Aggravate Aging-related Bone LossZhihao Chen, Ying Huai, Gaoyang Chen, et al.
Cell Death and Differentiation|May 10, 2022
Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancerJinrui Zhang, Ge Zhang, Wenjing Zhang, et al.
The Journal of Antimicrobial Chemotherapy|July 3, 2021
Establishment of epidemiological cut-off values for cefoselis, a new fourth-generation cephalosporin, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis and Pseudomonas aeruginosaXue Li, Peiyao Jia, Ying Zhu, et al.
Cell Metabolism|September 24, 2021
Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogrammingSamantha M Morrissey, Fan Zhang, Chuanlin Ding, et al.
BMC Anesthesiology|April 24, 2022
Learning to predict in-hospital mortality risk in the intensive care unit with attention-based temporal convolution networkYu-Wen Chen, Yu-Jie Li, Peng Deng, et al.
Nature Communications|February 10, 2022
The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progressionAnne E Geller, Rejeena Shrestha, Matthew R Woeste, et al.
Frontiers in Immunology|December 26, 2022
Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinomaFucun Xie, Bowen Chen, Xu Yang, et al.
Pageof 196